Antonella Gozzini

Age and d<scp>PCR</scp> can predict relapse in <scp>CML</scp> patients who discontinued imatinib: The <scp>ISAV</scp> study

Silvia Mori, Elisabetta Vagge, Philipp le Coutre et al. · American Journal of Hematology · 2015 · 207 citations · Full text

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

Simona Soverini, Alessandra Gnani, Sabrina Colarossi et al. · Blood · 2009 · 173 citations · Full text

<b><i>In Vitro</i></b>and<b><i>in Vivo</i></b>Activity of the Maytansinoid Immunoconjugate huN901-<b><i>N</i></b>2′-Deacetyl-<b><i>N</i></b>2′-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells

Pierfrancesco Tassone, Antonella Gozzini, Victor S. Goldmacher et al. · Cancer Research · 2004 · 152 citations

Immunotoxicology, Immunology, Immune Regulation +18

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

Simona Soverini, Caterina De Benedittis, Cristina Papayannidis et al. · Cancer · 2013 · 138 citations · Full text

Cytotoxic activity of the maytansinoid immunoconjugate B-B4–DM1 against CD138+ multiple myeloma cells

Pierfrancesco Tassone, Victor S. Goldmacher, Paola Neri et al. · Blood · 2004 · 124 citations · Full text